Using Syngenic Models to Understand the Molecular Pathways Leading to Improved STING Therapy Using vps34 Inhibitors
Time: 3:00 pm
day: Conference Day Two
Details:
- Inhibiting VPS34 enhances T-cell-recruiting chemokines through the activation of the cGAS/STING pathway
- Combining VPS34 inhibitors with STING agonist ADU-S100 improves tumour control in syngeneic mice models
- Exemplifying the use of syngeneic models in preclinical drug discovery to investigate molecular mechanisms that define the rationale for combination therapy
